Cidara Therapeutics Inc. | Income Statement
Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cost of Goods Sold (COGS) incl. D&A
-
179.00
461.00
732.00
667.00
523
Gross Income
-
179.00
461.00
732.00
667.00
523
SG&A Expense
1,082.00
9,837.00
31,852.00
47,704.00
55,054.00
62,762
EBIT
1,082.00
10,016.00
32,313.00
48,436.00
55,721.00
63,285
Unusual Expense
-
1,607.00
-
-
-
3,851
Interest Expense
262.00
271.00
-
22.00
7.00
-
Pretax Income
1,344.00
11,894.00
32,193.00
48,165.00
55,728.00
59,016
Consolidated Net Income
1,344.00
11,894.00
32,193.00
48,165.00
55,728.00
69,345
Net Income
1,344.00
11,894.00
32,193.00
48,165.00
55,728.00
69,345
Net Income After Extraordinaries
1,344.00
11,894.00
32,193.00
48,165.00
55,728.00
69,345
Net Income Available to Common
1,344.00
11,894.00
32,193.00
48,165.00
55,728.00
69,345
EPS (Basic)
0.09
0.84
3.25
3.32
3.18
2.76
Basic Shares Outstanding
14,214.10
14,214.10
9,920.40
14,489.00
17,500.90
25,143
EPS (Diluted)
0.09
0.84
3.25
3.32
3.18
2.76
Diluted Shares Outstanding
14,214.10
14,214.10
9,920.40
14,489.00
17,500.90
25,143
EBITDA
1,082.00
9,837.00
31,852.00
47,704.00
55,054.00
62,762
Non-Operating Interest Income
-
-
120.00
293.00
-
629
About Cidara Therapeutics
View Profile
